Francis Pang is Vice President and Head, Global Market Access at Orchard Therapeutics and has more than 20 years of
experience in pricing and reimbursement, market access and health economics, encompassing leadership roles at Amicus
Therapeutics, Biogen and Shire HGT. In recognition of his expertise related to rare diseases, Francis has served as the healthcare
industry representative on the NICE Highly Specialised Technologies (HST) Committee since its inception. He also co-chairs the
European Market Access and Value Committee of the Alliance for Regenerative Medicine (ARM). Prior to joining the
biopharmaceutical industry, Francis was the inaugural Pharmacoeconomics Research Fellow at the Centre for Health
Economics, University of York, UK and Monbusho Scholar at Kyoto University, Japan. Francis holds degrees in genetics and
health economics, together with an MBA from INSEAD and certification in the management of biotech ventures from École
Polytechnique Fédérale de Lausanne (EPFL).